(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.47%) $78.48
(0.33%) $2.15
(0.34%) $2 316.50
(1.67%) $27.14
(-0.53%) $960.15
(0.00%) $0.929
(-0.18%) $10.86
(-0.02%) $0.797
(0.00%) $91.45
-1.62% $ 82.44
@ $83.11
Emitido: 1 may 2024 @ 15:32
Retorno: -0.80%
Señal anterior: abr 30 - 15:32
Señal anterior:
Retorno: 2.70 %
Live Chart Being Loaded With Signals
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...
Stats | |
---|---|
Volumen de hoy | 1.63M |
Volumen promedio | 1.58M |
Capitalización de mercado | 15.65B |
EPS | $0 ( 2024-04-24 ) |
Próxima fecha de ganancias | ( $0.570 ) 2024-07-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 77.77 |
ATR14 | $2.27 (2.76%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Bienaime Jean Jacques | Buy | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
INSIDER POWER |
---|
25.83 |
Last 93 transactions |
Buy: 972 265 | Sell: 563 201 |
Volumen Correlación
Biomarin Pharmaceutical Correlación
10 Correlaciones Más Positivas | |
---|---|
MMAC | 0.923 |
RMRM | 0.916 |
FREQ | 0.89 |
ABST | 0.889 |
IMPL | 0.889 |
TTOO | 0.887 |
SGBX | 0.887 |
INFI | 0.885 |
SBBP | 0.884 |
CFV | 0.884 |
10 Correlaciones Más Negativas | |
---|---|
APOP | -0.956 |
ICON | -0.907 |
RDUS | -0.893 |
MIND | -0.88 |
TRMD | -0.879 |
WRLD | -0.878 |
SYKE | -0.875 |
BNIXU | -0.873 |
SOUN | -0.873 |
MGTX | -0.873 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Biomarin Pharmaceutical Correlación - Moneda/Commodity
Biomarin Pharmaceutical Finanzas
Annual | 2023 |
Ingresos: | $2.42B |
Beneficio Bruto: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2023 |
Ingresos: | $2.42B |
Beneficio Bruto: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2022 |
Ingresos: | $2.10B |
Beneficio Bruto: | $1.61B (76.92 %) |
EPS: | $0.760 |
FY | 2021 |
Ingresos: | $1.85B |
Beneficio Bruto: | $1.38B (74.52 %) |
EPS: | $-0.354 |
Financial Reports:
No articles found.
Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico